Bioramics is a biotechnology company focused on advancing a portfolio of soft tissue regeneration and disease programs, including Dystrophix, an injectable hypoxia mimetic for the pre-treatment of myofascial compartments of peripheral muscles of Duchenne muscle dystrophy (preparing them to receive systemic therapies while acutely enhancing function), TRIM for treatment

of human muscle injuries (enhancing regeneration),

and pyr341, a stent coating that reduces calcification. Bioramics aims to be the hub for comprehensive applications of extended release ion matrices, safe for injection into soft tissues. Our team is positioned to make an incredible impact in the lives of those suffering from soft tissue injuries and diseases.